IPSEN (OTCMKTS:IPSEY) Reaches New 1-Year High – Still a Buy?

IPSEN (OTCMKTS:IPSEY) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $39.10 and last traded at $39.10, with a volume of 610 shares. The stock had previously closed at $37.57.

Analysts Set New Price Targets

IPSEY has been the subject of several research analyst reports. UBS Group cut IPSEN from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 8th. BNP Paribas lowered IPSEN to an “underperform” rating in a research note on Wednesday, November 26th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a report on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold”.

IPSEN Stock Performance

The stock’s 50 day simple moving average is $36.25 and its two-hundred day simple moving average is $34.17.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).